InduPro
InduPro develops protein-proximity platforms and therapeutics that identify and manipulate interactions between cell-surface proteins, including antibody-based modalities that bring proteins together to alter signaling. Its platforms support discovery of therapeutic targets and development of treatments for disease, with the goal of creating next-generation medicines for patients.
Facts
- HQ
- Seattle, WA, US
- Sectors
- Biotechnology
- Founded
- 2022
- Type
- Corporation Seattle business license
- Employees
- 11–50
- Registered name
- InduPro Inc Seattle business license
- Stage
- Series B
Is this your organization? Claim it
Stoke Space’s $1B Series E Propels Seattle Metro to $3.5B in VC Funding Across 94 Q3 Deals
Seattle-area VC activity surged in Q3 as Stoke Space led with a $1 billion Series E initial close and the region raised $3.5 billion across 94 deals, its strongest quarter in at least a decade.
InduPro Announces Nature Publication Establishing Spatial Protein Proximity as Framework for Therapeutic Discovery
InduPro reports that a paper in Nature establishes spatial protein proximity as a new framework for discovering therapeutics, advancing their approach to cancer and autoimmune disease drug development.
InduPro raises $77M Series B, doses first patient in Phase 1 trial of IDP-001 targeting tumor protein pairs
InduPro raised $77 million in Series B financing and has dosed the first patient in a Phase 1 trial of IDP-001, an antibody-drug conjugate that uses the company’s ARRIS platform to target cancer cells by bringing two surface proteins together.
See all 8 stories, episodes and videos about InduPro.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
See all 4-
Amanda J. Redig Executive, Chief Medical Officer
-
Amanda Redig Executive, Chief Medical Officer
-
Prakash Raman Executive, CEO